NCT04964544 - Technology-Assisted Cholesterol Trial in Consumers (TACTiC) | Biotech Hunter

Enrollment

1,196

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions

High Cholesterol

Interventions

COMBINATION_PRODUCT

5 mg rosuvastatin calcium with a Web App (combination product)

The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.

Trial Locations (1)

46240

Research Site, Indianapolis